Immutep is a late-stage clinical biotechnology company developing novel LAG-3 immunotherapies to fight cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and harness its unique ability to stimulate or suppress the immune response. Our diversified product portfolio includes eftilagimod alpha, a proprietary soluble LAG-3 protein and MHC Class II agonist in oncology, and IMP761, the world's first LAG-3 agonist designed to target the underlying causes of autoimmune diseases. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
View Top Employees from Immutep LimitedWebsite | http://www.immutep.com/ |
Ticker | NASDAQ:IMMP |
Revenue | $3.2 million |
Employees | 51 (51 on RocketReach) |
Founded | 2001 |
Address | Level 33, Australia Square 264 George Street, Sydney, New South Wales 2000, AU |
Phone | +61 2 9276 1224 |
Fax | +61 2 8569 1880 |
Technologies |
HTML,
PHP,
Google Analytics
+15 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology, Biotechnology Research, Clinical Trials, Healthcare, Health Care, Pharmaceutical, Drug Manufacturing & Research |
Web Rank | 30 Million |
SIC | SIC Code 37 Companies, SIC Code 372 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 3254 Companies |
Looking for a particular Immutep Limited employee's phone or email?
The Immutep Limited annual revenue was $3.2 million in 2024.
Russell Howard is the Chairman of the Board of Immutep Limited.
51 people are employed at Immutep Limited.
Immutep Limited is based in Sydney, New South Wales.
The NAICS codes for Immutep Limited are [32, 32541, 54, 325, 541, 5417, 3254].
The SIC codes for Immutep Limited are [37, 372].